These results demonstrated that BCLX-specific SSOs allowed Bcl-xL to switch to Bcl-xS, efficiently reversed the abnormal splicing of BCLX gene in A172 cells (Fig. 2G), and can be used as a potential therapeutic target for GBM. The gene discussed is BCL2L1; the disease is glioblastoma.